- 0
Highlights & Basics
- Uveitis is a broad term for inflammation of one or all parts of the uvea, or the vascular area between the retina and sclera of the eye. Uveitis can be acute, recurrent, or chronic.
- All types of uveitis are potentially blinding conditions and should be referred to and managed by an experienced ophthalmologist.
- Diagnosis is clinical. Onset and duration of the ocular symptoms offer clues to the etiology. Even after full laboratory and diagnostic workup and treatment, etiology may not be determined.
- Treatment for systemic disease causing uveitis must be given in conjunction with uveitis therapy.
- Topical ophthalmic corticosteroids are usually adequate for acute noninfectious anterior uveitis, but intermediate and posterior uveitis usually requires local corticosteroid injections or systemic corticosteroids, or other immunosuppressants.
Quick Reference
History & Exam
Key Factors
Other Factors
Diagnostics Tests
Treatment Options
Definition
Epidemiology
Etiology
Pathophysiology
Images
Citations
Deschenes J, Murray PI, Rao NA, et al; International Uveitis Study Group. International Uveitis Study Group (IUSG): clinical classification of uveitis. Ocul Immunol Inflamm. 2008 Jan-Feb;16(1):1-2.[Abstract]
Jabs DA, Nussenblatt RD, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol. 2005 Sep;140(3):509-16.[Abstract]
Foster CS, Kothari S, Anesi SD, et al. The Ocular Immunology and Uveitis Foundation preferred practice patterns of uveitis management. Surv Ophthalmol. 2016 Jan-Feb;61(1):1-17.[Abstract]
Dick AD, Rosenbaum JT, Al-Dhibi HA, et al. Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative. Ophthalmology. 2018 May;125(5):757-73.[Abstract][Full Text]
1. Deschenes J, Murray PI, Rao NA, et al; International Uveitis Study Group. International Uveitis Study Group (IUSG): clinical classification of uveitis. Ocul Immunol Inflamm. 2008 Jan-Feb;16(1):1-2.[Abstract]
2. Jabs DA, Nussenblatt RD, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol. 2005 Sep;140(3):509-16.[Abstract]
3. Burkholder BM, Jabs DA. Uveitis for the non-ophthalmologist. BMJ. 2021 Feb 3;372:m4979.[Abstract]
4. Acharya NR, Tham VM, Esterberg E, et al. Incidence and prevalence of uveitis: results from the Pacific Ocular Inflammation Study. JAMA Ophthalmol. 2013 Nov;131(11):1405-12.[Abstract][Full Text]
5. Gritz DG, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology. 2004 Mar;111(3):491-500.[Abstract]
6. Kung TP, Hunt MS, McKay M, et al. Uveitis incidence in the United States (US): a database study using the Intelligent Research in Sight (IRIS)® registry. IOVS. 2021 Jun;62(8):1404.[Full Text]
7. Suhler EB, Lloyd MJ, Choi D, et al. Incidence and prevalence of uveitis in veterans affairs medical centers of the Pacific Northwest. Am J Ophthalmol. 2008 Dec;146(6):890-6.e8.[Abstract]
8. González MM, Solano MM, Porco TC, et al. Epidemiology of uveitis in a US population-based study. J Ophthalmic Inflamm Infect. 2018 Apr 17;8(1):6.[Abstract][Full Text]
9. Amin S, Seabury SA, Rao MA, et al. Measuring the incidence and prevalence of uveitis and scleritis in a national medical claims database. 2019 Jul;60(9):6658.[Full Text]
10. Abdulaal MR, Abiad BH, Hamam RN. Uveitis in the aging eye: incidence, patterns, and differential diagnosis. J Ophthalmol. 2015;2015:509456.[Abstract][Full Text]
11. Barisani-Asenbauer T, Maca SM, Mejdoubi L, et al. Uveitis: a rare disease often associated with systemic diseases and infections - a systematic review of 2619 patients. Orphanet J Rare Dis. 2012 Aug 29;7:57.[Abstract][Full Text]
12. Miserocchi E, Fogliato G, Modorati G, et al. Review on the worldwide epidemiology of uveitis. Eur J Ophthalmol. 2013 Sep-Oct;23(5):705-17.[Abstract]
13. Tsirouki T, Dastiridou A, Symeonidis C, et al. A focus on the epidemiology of uveitis. Ocul Immunol Inflamm. 2018;26(1):2-16.[Abstract]
14. Murray CJ, Ortblad KF, Guinovart C, el al; GBD Study group. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014 Sep 13;384(9947):1005-70.[Abstract][Full Text]
15. Radosavljevic A, Agarwal M, Chee SP, et al. Epidemiology of viral induced anterior uveitis. Ocul Immunol Inflamm. 2021 Feb 22;1-13.[Abstract]
16. Lee JH, Agarwal A, Mahendradas P, et al. Viral posterior uveitis. Surv Ophthalmol. 2017 Jul-Aug;62(4):404-45.[Abstract][Full Text]
17. Jackson TL. Moorfields manual of ophthalmology. 3rd ed. London: Jaypee Brothers Medical Publishers; 2019.
18. McCluskey PJ, Towler HM, Lightman S. Management of chronic uveitis. BMJ. 2000 Feb 26;320(7234):555-8.[Abstract][Full Text]
19. Bertrand PJ, Jamilloux Y, Ecochard R, et al. Uveitis: autoimmunity... and beyond. Autoimmun Rev. 2019 Sep;18(9):102351.[Abstract]
20. Rosenbaum JT. Uveitis: an internist's view. Arch Intern Med. 1989 May;149(5):1173-6.[Abstract]
21. Kalogeropoulos D, Asproudis I, Stefaniotou M, et al. The large Hellenic study of uveitis: epidemiology, etiologic factors and classification. Int Ophthalmol. 2023 Oct;43(10):3633-50.[Abstract][Full Text]
22. Oh BL, Lee JS, Lee EY, et al. Recurrent anterior uveitis and subsequent incidence of ankylosing spondylitis: a nationwide cohort study from 2002 to 2013. Arthritis Res Ther. 2018 Feb 7;20(1):22.[Abstract][Full Text]
23. Wensing B, Mochizuki M, De Boer JH. Clinical characteristics of herpes simplex virus associated anterior uveitis. Ocul Immunol Inflamm. 2018;26(3):333-7.[Abstract][Full Text]
24. Bhikoo R, Damato EM, Guest S, et al. Primary ocular toxoplasmosis presenting to uveitis services in a non-endemic setting. Korean J Ophthalmol. 2019 Dec;33(6):514-9.[Abstract][Full Text]
25. Mandelcorn ED. Infectious causes of posterior uveitis. Can J Ophthalmol. 2013 Feb;48(1):31-9.[Abstract][Full Text]
26. London NJ, Garg SJ, Moorthy RS, et al. Drug-induced uveitis. J Ophthalmic Inflamm Infect. 2013 Mar 25;3(1):43.[Abstract][Full Text]
27. Fournier S, Deplus S, Janier M, et al. Anterior uveitis in HIV-infected patients: 3 cases in patients treated with an antiprotease [in French]. Presse Med. 1998 May 16;27(18):844-8.[Abstract]
28. Kunavisarut P, Sirirungsi W, Pathanapitoon K, et al. Clinical manifestations of human immunodeficiency virus-induced uveitis. Ophthalmology. 2012 Jul;119(7):1455-9.[Abstract]
29. King D, Chandan JS, Thomas T, et al. Risk of a subsequent diagnosis of inflammatory bowel disease in subjects with ophthalmic disorders associated with inflammatory bowel disease: a retrospective cohort analysis of UK primary care data. BMJ Open. 2022 May 11;12(5):e052833.[Abstract][Full Text]
30. Papasavvas I, Kuiper JJW, Herbort CP Jr. Some practical issues about HLA-A29 in birdshot retinochoroiditis. J Ophthalmic Inflamm Infect. 2023 Mar 9;13(1):10.[Abstract][Full Text]
31. Cunningham ET Jr. Uveitis in children. Ocul Immunol Inflamm. 2000 Dec;8(4):251-61.[Abstract]
32. Margery-Muir AA, Bundell C, Nelson D, et al. Gender balance in patients with systemic lupus erythematosus. Autoimmun Rev. 2017 Mar;16(3):258-68.[Abstract]
33. Rees F, Doherty M, Grainge M, et al. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. Ann Rheum Dis. 2016 Jan;75(1):136-41.[Abstract][Full Text]
34. Michet CJ Jr, McKenna CH, Elveback LR, et al. Epidemiology of systemic lupus erythematosus and other connective tissue diseases in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc. 1985 Feb;60(2):105-13.[Abstract]
35. Flower C, Hennis AJ, Hambleton IR, et al. Systemic lupus erythematosus in an African Caribbean population: incidence, clinical manifestations, and survival in the Barbados National Lupus Registry. Arthritis Care Res (Hoboken). 2012 Aug;64(8):1151-8.[Abstract][Full Text]
36. Hena KM. Sarcoidosis epidemiology: race matters. Front Immunol. 2020 Sep 15;11:537382.[Abstract][Full Text]
37. American Thoracic Society; European Respiratory Society; World Association of Sarcoidosis and Other Granulomatous Disorders. Statement on sarcoidosis: joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999 Aug;160(2):736-55.[Abstract][Full Text]
38. Saadoun D, Wechsler B. Behçet's disease. Orphanet J Rare Dis. 2012 Apr 12;7:20.[Abstract][Full Text]
39. Lavezzo MM, Sakata VM, Morita C, et al. Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes. Orphanet J Rare Dis. 2016 Mar 24;11:29.[Abstract][Full Text]
40. American Academy of Ophthalmology. Primary angle-closure disease preferred practice pattern. Nov 2020 [internet publication].[Full Text]
41. Chang MH, Shantha JG, Fondriest JJ, et al. Uveitis in children and adolescents. Rheum Dis Clin North Am. 2021 Nov;47(4):619-41.[Abstract][Full Text]
42. Agrawal RV, Murthy S, Sangwan V, et al. Current approach in diagnosis and management of anterior uveitis. Indian J Ophthalmol. 2010 Jan-Feb;58(1):11-9.[Abstract][Full Text]
43. Terada Y, Kaburaki T, Takase H, et al. Distinguishing features of anterior uveitis caused by herpes simplex virus, varicella-zoster virus, and cytomegalovirus. Am J Ophthalmol. 2021 Jul;227:191-200.[Abstract]
44. Centers for Disease Control and Prevention. Bacille Calmette-Guérin (BCG) vaccine for tuberculosis. Jan 2025 [internet publication].[Full Text]
45. Kalogeropoulos D, Sakkas H, Mohammed B, et al. Ocular toxoplasmosis: a review of the current diagnostic and therapeutic approaches. Int Ophthalmol. 2022 Jan;42(1):295-321.[Abstract][Full Text]
46. Jeroudi A, Yeh S. Diagnostic vitrectomy for infectious uveitis. Int Ophthalmol Clin. 2014 Spring;54(2):173-97.[Abstract][Full Text]
47. McKay KM, Jacobs DS. In vivo confocal microscopy of keratic precipitates in uveitis. Int Ophthalmol Clin. 2019 Fall;59(4):95-103.[Abstract]
48. Kaburaki T, Fukunaga H, Tanaka R, et al. Retinal vascular inflammatory and occlusive changes in infectious and non-infectious uveitis. Jpn J Ophthalmol. 2020 Mar;64(2):150-9.[Abstract]
49. Gueudry J, Muraine M. Anterior uveitis. J Fr Ophtalmol. 2018 Jan;41(1):e11-21.[Abstract]
50. Liu X, Kelly SR, Montesano G, et al. Evaluating the impact of uveitis on visual field progression using large-scale real-world data. Am J Ophthalmol. 2019 Nov;207:144-50.[Abstract][Full Text]
51. Vaze A, De Angelis RE, Simões M, et al. Optical coherence tomography findings in ocular syphilis involving the posterior segment of the eye. Ocul Immunol Inflamm. 2022 Aug;30(6):1464-70.[Abstract]
52. Liu XY, Peng XY, Wang S, et al. Features of optical coherence tomography for the diagnosis of Vogt-Koyanagi-Harada disease. Retina. 2016 Nov;36(11):2116-23.[Abstract]
53. American Society for Clinical Pathology. Thirty five things physicians and patients should question. Choosing Wisely, an initiative of the ABIM Foundation. 2021 [internet publication].[Full Text]
54. Thillai M, Atkins CP, Crawshaw A, et al. BTS clinical statement on pulmonary sarcoidosis. Thorax. 2021 Jan;76(1):4-20.[Abstract][Full Text]
55. The Thoracic Society of Australia and New Zealand. Do not perform a serum ACE for the diagnosis or monitoring of sarcoidosis. Choosing Wisely Australia, an initiative of NPS MedicineWise. Jun 2021 [internet publication].[Full Text]
56. von Mühlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum. 1995 Apr;24(5):323-58.[Abstract]
57. Colucciello M. Ocular Lyme borreliosis. N Engl J Med. 2001 Nov 1;345(18):1350-1.[Abstract]
58. Ahram DF, Alward WL, Kuehn MH. The genetic mechanisms of primary angle closure glaucoma. Eye (Lond). 2015 Oct;29(10):1251-9.[Abstract][Full Text]
59. Smith JR, Rosenbaum JT. Management of uveitis: a rheumatologic perspective. Arthritis Rheum. 2002 Feb;46(2):309-18.[Abstract]
60. Foster CS, Kothari S, Anesi SD, et al. The Ocular Immunology and Uveitis Foundation preferred practice patterns of uveitis management. Surv Ophthalmol. 2016 Jan-Feb;61(1):1-17.[Abstract]
61. Mercieca K, Sanghvi C, Jones NP. Spontaneous sub-conjunctival haemorrhage in patients using long-term topical corticosteroids. Eye (Lond). 2010 Dec;24(12):1770-1.[Abstract][Full Text]
62. Sen HN, Vitale S, Gangaputra SS, et al. Periocular corticosteroid injections in uveitis: effects and complications. Ophthalmology. 2014 Nov;121(11):2275-86.[Abstract][Full Text]
63. Feldman-Billard S, Du Pasquier-Fediaevsky L, Héron E. Hyperglycemia after repeated periocular dexamethasone injections in patients with diabetes. Ophthalmology. 2006 Oct;113(10):1720-3.[Abstract]
64. Polski A, Liu KC, Gupta D, et al. Incident glaucoma and ocular hypertension after periocular and intravitreal steroid injections: a claims-based analysis. BMJ Open Ophthalmol. 2023 Dec 22;8(1):e001508.[Abstract][Full Text]
65. José-Vieira R, Ferreira A, Menéres P, et al. Efficacy and safety of intravitreal and periocular injection of corticosteroids in noninfectious uveitis: a systematic review. Surv Ophthalmol. 2022 Jul-Aug;67(4):991-1013.[Abstract]
66. Reichle ML. Complications of intravitreal steroid injections. Optometry. 2005 Aug;76(8):450-60.[Abstract]
67. Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006 Jun;113(6):1020-7.[Abstract]
68. American Academy of Ophthalmology. EyeWiki: treatment of uveitis. Dec 2023 [internet publication].[Full Text]
69. Rice JB, White AG, Scarpati LM, et al. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther. 2017 Nov;39(11):2216-29.[Abstract][Full Text]
70. Losada I, Sartori L, Di Gianantonio E, et al. Bisphosphonates in patients with autoimmune rheumatic diseases: Can they be used in women of childbearing age? Autoimmun Rev. 2010 Jun;9(8):547-52.[Abstract]
71. Dick AD, Rosenbaum JT, Al-Dhibi HA, et al. Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative. Ophthalmology. 2018 May;125(5):757-73.[Abstract][Full Text]
72. Jabs DA. Immunosuppression for the uveitides. Ophthalmology. 2018 Feb;125(2):193-202.[Abstract][Full Text]
73. Kempen JH, Altaweel MM, Holbrook JT, et al; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology. 2011 Oct;118(10):1916-26.[Abstract][Full Text]
74. Reddy A, Liu SH, Brady CJ, et al. Corticosteroid implants for chronic non-infectious uveitis. Cochrane Database Syst Rev. 2023 Aug 29;8(8):CD010469.[Abstract][Full Text]
75. Kempen JH, Altaweel MM, Holbrook JT, et al; Writing Committee for the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study Research Group. Association between long-lasting intravitreous fluocinolone acetonide implant vs systemic anti-inflammatory therapy and visual acuity at 7 years among patients with intermediate, posterior, or panuveitis. JAMA. 2017 May 16;317(19):1993-2005.[Abstract]
76. Edwards Mayhew RG, Li T, McCann P, et al. Non-biologic, steroid-sparing therapies for non-infectious intermediate, posterior, and panuveitis in adults. Cochrane Database Syst Rev. 2022 Oct 31;10(10):CD014831.[Abstract][Full Text]
77. Cuchacovich M, Solanes F, Díaz G, et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. 2010 Jun;18(3):200-7.[Abstract]
78. Galor A, Jabs DA, Leder HA, et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology. 2008 Oct;115(10):1826-32.[Abstract]
79. Murphy CC, Greiner K, Plskova J, et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol. 2005 May;123(5):634-41.[Abstract][Full Text]
80. Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016 Sep 8;375(10):932-43.[Abstract][Full Text]
81. Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016 Sep 17;388(10050):1183-92.[Abstract]
82. National Institute for Health and Care Excellence. Adalimumab and dexamethasone for treating non-infectious uveitis. Jul 2017 [internet publication].[Full Text]
83. Liu W, Bai D, Kou L. Comparison of infliximab with adalimumab for the treatment of non-infectious uveitis: a systematic review and meta-analysis. BMC Ophthalmol. 2023 May 29;23(1):240.[Abstract][Full Text]
84. Renton WD, Jung J, Palestine AG. Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis-associated uveitis. Cochrane Database Syst Rev. 2022 Oct 14;10(10):CD013818.[Abstract][Full Text]
85. Guan X, Zhao Z, Xin M, et al. Long-term efficacy, safety, and cumulative retention rate of antitumor necrosis factor-alpha treatment for patients with Behcet's uveitis: a systematic review and meta-analysis. Int J Rheum Dis. 2024 Feb;27(2):e15096.[Abstract]
86. Busto-Iglesias M, Rodríguez-Martínez L, Rodríguez-Fernández CA, et al. Perspectives of therapeutic drug monitoring of biological agents in non-infectious uveitis treatment: a review. Pharmaceutics. 2023 Feb 25;15(3):766.[Abstract][Full Text]
87. Ng CC, Sy A, Cunningham ET Jr. Rituximab for non-infectious uveitis and scleritis. J Ophthalmic Inflamm Infect. 2021 Aug 16;11(1):23.[Abstract][Full Text]
88. Miserocchi E, Modorati G, Berchicci L, et al. Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis. Br J Ophthalmol. 2016 Jun;100(6):782-6.[Abstract]
89. Ahmed A, Foster CS. Cyclophosphamide or rituximab treatment of scleritis and uveitis for patients with granulomatosis with polyangiitis. Ophthalmic Res. 2019;61(1):44-50.[Abstract]
90. You C, Ma L, Lasave AF, et al. Rituximab induction and maintenance treatment in patients with scleritis and granulomatosis with polyangiitis (Wegener's). Ocul Immunol Inflamm. 2018;26(8):1166-73.[Abstract]
91. Chiam NP, Lim LL. Uveitis and gender: the course of uveitis in pregnancy. J Ophthalmol. 2014;2014:401915.[Abstract][Full Text]
92. Bandoli G, Palmsten K, Forbess Smith CJ, et al. A review of systemic corticosteroid use in pregnancy and the risk of select pregnancy and birth outcomes. Rheum Dis Clin North Am. 2017 Aug;43(3):489-502.[Abstract][Full Text]
93. Chambers CD, Johnson DL, Xu R, et al. Birth outcomes in women who have taken adalimumab in pregnancy: a prospective cohort study. PLoS One. 2019;14(10):e0223603.[Abstract][Full Text]
94. Ngathaweesuk Y, Hendrikse J, Groot-Mijnes JDF, et al. Causes of infectious pediatric uveitis: a review. Surv Ophthalmol. 2024 May-Jun;69(3):483-94.[Abstract][Full Text]
95. Merrill PT, Clark WL, Banker AS, et al. Efficacy and safety of intravitreal sirolimus for noninfectious uveitis of the posterior segment: results from the sirolimus study assessing double-masked uveitis treatment (SAKURA) program. Ophthalmology. 2020 Oct;127(10):1405-15.[Abstract][Full Text]
96. Hassan M, Sadiq MA, Ormaechea MS, et al. Utilisation of composite endpoint outcome to assess efficacy of tocilizumab for non-infectious uveitis in the STOP-Uveitis Study. Br J Ophthalmol. 2023 Aug;107(8):1197-201.[Abstract][Full Text]
97. Ramanan AV, Guly CM, Keller SY, et al. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT). Trials. 2021 Oct 9;22(1):689.[Abstract][Full Text]
98. ClinicalTrials.gov. A study of brepocitinib in adults with active non-infectious non-anterior uveitis (NEPTUNE). Nov 2024 [internet publication].[Full Text]
99. Yeh S, Khurana RN, Shah M, et al. Efficacy and safety of suprachoroidal CLS-TA for macular edema secondary to noninfectious uveitis: phase 3 randomized trial. Ophthalmology. 2020 Jul;127(7):948-55.[Abstract][Full Text]
100. ClinicalTrials.gov. Ixekizumab for the management of refractory non-infectious uveitis: a proof-of-concept study. Oct 2023 [internet publication].[Full Text]
101. Jackson ML, Virgili G, Shepherd JD, et al. Vision rehabilitation preferred practice pattern®. Ophthalmology. 2023 Mar;130(3):P271-335.[Abstract][Full Text]
102. Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014 Mar;121(3):785-96;e3.[Abstract]
103. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, et al. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996 Apr;80(4):332-6.[Abstract][Full Text]
104. Chen JL, Bhat P, Lobo-Chan AM. Perioperative management of uveitic cataracts. Adv Ophthalmol Optom. 2019 Aug;4:325-39.[Abstract][Full Text]
105. Gopalakrishnan S, Sudharshan S, Raman R, et al. Visual rehabilitation of patients with low vision in uveitis. Indian J Ophthalmol. 2019 Jan;67(1):101-4.[Abstract][Full Text]
